Archive for May, 2008
GenVec Presents Encouraging details On TNFerade(TM) In Esophageal Cancer
GenVec, Inc. (Nasdaq:GNVC) presented an overview of TNFerade™ development and an update on long-term survival details from its Phase II clinical trial using TNFerade in patients with esophageal cancer at the American Society of Gene Therapy (ASGT) 11th Annual Meeting in Boston, MA. Dr.
Original post by Women’s Health / Gynecology News From Medical News Today
Challenges Associated With Vulvar Pain Disorder
Vulvar vestibulitis syndrome (vvs), a vulvar pain disorder, affects approximately 15 percent of women. A new study in the journal Family Process reviews the experiences of couples in which the woman has a diagnosis of vvs and explores coping strategies that aid in the subsequent emotional, relational, and sexual challenges. There is no known cause or decisive treatment.Researchers including Jennifer J.
Original post by Women’s Health / Gynecology News From Medical News Today
About 60 Clinical Studies Regarding Schering-Plough’s Oncology Compounds Will Be Presented At ASCO
Schering-Plough Corporation (NYSE: SGP) announced that about 80 posters, poster discussions, and oral presentations from about 60 clinical studies relating to its growing oncology franchise will be presented at the upcoming 44th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, May 30 - June 3.
Original post by Women’s Health / Gynecology News From Medical News Today
Wyeth Initiates INTORACT — A New Clinical Trial To Examine TORISEL Plus Avastin For First-Line Treatment Of Advanced Kidney Cancer
Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), announced the initiation of the INTORACT (INvestigation of TORISEL and Avastin Combination Therapy) study, a worldwide randomized, open-label, phase 3b study comparing TORISEL(R) (temsirolimus) plus Avastin(R) (bevacizumab) versus Avastin plus interferon-alfa for first-line treatment of patients with advanced renal cell carcinoma (RCC).
Original post by Women’s Health / Gynecology News From Medical News Today
Human Genome Sciences Initiates First Clinical Trial Of Lead IAP Inhibitor HGS1029 In Advanced Solid Tumors
Human Genome Sciences, Inc. (Nasdaq: HGSI) announced that it has initiated dosing in a Phase 1 clinical trial to evaluate the safety and tolerability of its lead IAP inhibitor, HGS1029, as monotherapy in patients with advanced solid tumors.
Original post by Women’s Health / Gynecology News From Medical News Today
The Coffey Lectureship - Heat Shock Protein 90: A Molecular Chaperone As Anti-Cancer Molecular Target
ORLANDO, FL (UroToday.com) - In a joint meeting of the SBUR and SUO, Dr. Len Neckers discussed Hsp90 as a cancer target. Heat shock proteins are involved in protein synthesis. Early on it was noted that heat increases transcription of HSP genes in the Drosophila. Heat shock proteins were thus identified. HSPs are additionally referred to molecular chaperones due to their functional role.
Original post by Women’s Health / Gynecology News From Medical News Today
Society Of Urologic Oncology Meeting - When Is It date To Treat The Patient And Not The Bladder?
ORLANDO, FL (UroToday.com) - Dr. Bochner outlined the dilemma of T1G3 bladder cancer. IT is a deadly disease whether conservative therapies are too liberally pursued. A thorough risk assessment must be performed, starting with restaging TURBT, detailed pathological review and optimal imaging prior to the TURBT and a bimanual examination.Risk factors include morphologic and pathologic characteristics. Sessile T1 lesions do significantly worse than papillary T1 lesions.
Original post by Women’s Health / Gynecology News From Medical News Today
